Dioseve is developing ReproNest (development code DIOS-101), a co-culture IVM product that uses ovarian support cell-like cells differentiated from iPS cells to support maturation of immature oocytes. The co-culture approach cultivates patient-derived oocytes together with support cells in the same system and is not intended as a cell therapy for administration into the body. Non-clinical studies reported by the company have shown potential benefits in supporting oocyte maturation compared with conventional IVM culture conditions. The company's technological strength is its proprietary differentiation induction technology, which it says enables efficient induction of oocytes and ovarian somatic cells from iPS cells and production of ovarian support cell-like cells. Dioseve sees applications in fertility preservation (including oocyte freezing), treatment of patients at high risk of OHSS, and rapid fertility preservation before cancer treatment. The recent funding will support validation, manufacturing and quality control setup, reproducibility assessment, regulatory compliance work, and business development to advance ReproNest toward practical application.

Total raised

$16M

Funding rounds

3

Latest round

Series A

Latest activity

Jun 2026